BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)

Reuters01-21

Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:

DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA $(HAE)$
IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALES

Source text: ID:nBw1hfhy7a

Further company coverage: IONS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605101164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605101164","market":"nz","top_or_hot":-1,"title":"BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span>Ionis Pharmaceuticals Inc <span>IONS.O</span>:</p><ul><li><p>DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a></p></li><li><p>IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALES</p></li></ul><p>Source text: <span>ID:nBw1hfhy7a</span></p><p>Further company coverage: <span>IONS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)</title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span>Ionis Pharmaceuticals Inc <span>IONS.O</span>:</p><ul><li><p>DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a></p></li><li><p>IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALES</p></li></ul><p>Source text: <span>ID:nBw1hfhy7a</span></p><p>Further company coverage: <span>IONS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA4TCGZN:1","article_id":"2605101164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605101164","pubTimestamp":1768997088,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Dawnzera (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:DAWNZERA (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc","BK4139":"生物科技"},"translate_title":"简介-Dawnzera™（Donidalorsen）在欧盟获批用于遗传性血管性水肿（Hae）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA $(HAE)$IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALESSource text: ID:nBw1hfhy7aFurther company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605101164","isCrawlerRequest":true}